Tags

Type your tag names separated by a space and hit enter

HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Cancer. 2005 Mar 01; 103(5):900-5.C

Abstract

BACKGROUND

Although p53 and HER-2/neu overexpression are found in 30% of breast carcinomas in women of all ages and are associated with high rates of lymph node metastases, their role in women age < 30 years has not been studied extensively.

METHODS

The institutional breast cancer data base was searched to identify young women (23-30 years) with breast carcinoma. An immunohistochemical analysis was performed to determine estrogen receptor and progesterone receptor expression and p53 and HER-2/neu overexpression. Positive staining for p53 was defined as nuclear staining in > 10% of tumor cells. HER-2/neu membranous staining was graded as 0, 1 (incomplete, faint staining in > 10% of cells), 2 (weak-to-moderate, complete staining in > 10% of cells), or 3 (complete, strong staining in > 10% of cells). Fluorescence in situ hybridization (FISH) was performed on all samples with > or = 2 and > or = 3 results, and only FISH-positive samples were classified as positive. The overexpression was correlated with clinicopathologic features.

RESULTS

Among 44 patients, 1 patient had medullary carcinoma, and 1 had mixed ductal/lobular carcinoma. All remaining patients were diagnosed with invasive ductal carcinoma. The clinical stage was T1 in 5 patients, T2 in 24 patients, T3 in 10 patients, T4 in 4 patients, and unavailable in 1 patient. Positive p53 status was determined in 22 of 44 patients (50%), and positive HER-2/neu status was determined in 18 of 41 patients (44%). Tumors with lymph node metastasis had a significantly greater incidence of HER-2/neu overexpression (P=0.04).

CONCLUSIONS

Frequent overexpression of HER-2/neu and p53 was found in the patient population. HER-2/neu overexpression was associated significantly with lymph node involvement and, thus, may be a marker for aggressive clinical behavior in patients with breast carcinoma age < or = 30 years.

Authors+Show Affiliations

Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15643600

Citation

Maru, Dipen, et al. "HER-2/neu and P53 Overexpression as Biomarkers of Breast Carcinoma in Women Age 30 Years and Younger." Cancer, vol. 103, no. 5, 2005, pp. 900-5.
Maru D, Middleton LP, Wang S, et al. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer. 2005;103(5):900-5.
Maru, D., Middleton, L. P., Wang, S., Valero, V., & Sahin, A. (2005). HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer, 103(5), 900-5.
Maru D, et al. HER-2/neu and P53 Overexpression as Biomarkers of Breast Carcinoma in Women Age 30 Years and Younger. Cancer. 2005 Mar 1;103(5):900-5. PubMed PMID: 15643600.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. AU - Maru,Dipen, AU - Middleton,Lavinia P, AU - Wang,Sijan, AU - Valero,Vicente, AU - Sahin,Aysegul, PY - 2005/1/12/pubmed PY - 2005/3/30/medline PY - 2005/1/12/entrez SP - 900 EP - 5 JF - Cancer JO - Cancer VL - 103 IS - 5 N2 - BACKGROUND: Although p53 and HER-2/neu overexpression are found in 30% of breast carcinomas in women of all ages and are associated with high rates of lymph node metastases, their role in women age < 30 years has not been studied extensively. METHODS: The institutional breast cancer data base was searched to identify young women (23-30 years) with breast carcinoma. An immunohistochemical analysis was performed to determine estrogen receptor and progesterone receptor expression and p53 and HER-2/neu overexpression. Positive staining for p53 was defined as nuclear staining in > 10% of tumor cells. HER-2/neu membranous staining was graded as 0, 1 (incomplete, faint staining in > 10% of cells), 2 (weak-to-moderate, complete staining in > 10% of cells), or 3 (complete, strong staining in > 10% of cells). Fluorescence in situ hybridization (FISH) was performed on all samples with > or = 2 and > or = 3 results, and only FISH-positive samples were classified as positive. The overexpression was correlated with clinicopathologic features. RESULTS: Among 44 patients, 1 patient had medullary carcinoma, and 1 had mixed ductal/lobular carcinoma. All remaining patients were diagnosed with invasive ductal carcinoma. The clinical stage was T1 in 5 patients, T2 in 24 patients, T3 in 10 patients, T4 in 4 patients, and unavailable in 1 patient. Positive p53 status was determined in 22 of 44 patients (50%), and positive HER-2/neu status was determined in 18 of 41 patients (44%). Tumors with lymph node metastasis had a significantly greater incidence of HER-2/neu overexpression (P=0.04). CONCLUSIONS: Frequent overexpression of HER-2/neu and p53 was found in the patient population. HER-2/neu overexpression was associated significantly with lymph node involvement and, thus, may be a marker for aggressive clinical behavior in patients with breast carcinoma age < or = 30 years. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/15643600/HER_2/neu_and_p53_overexpression_as_biomarkers_of_breast_carcinoma_in_women_age_30_years_and_younger_ L2 - https://doi.org/10.1002/cncr.20850 DB - PRIME DP - Unbound Medicine ER -